Table 1 (abstract P26). Results from final ranking survey. Top 7 priorities from each group, ranked from highest to lowest priorities
AF | Cure JM* | LFA* |
|---|---|---|
Genetic/Environmental Etiology | New Treatments | Genetic/Environmental Etiology |
Personalized medicine | Flares (triggers, prevention, treatment) | Quality of life |
Medication side effects | Medication side effects | Medication side effects |
Growth and development | Standards to measure disease activity and/or remission | Pain management |
Flares (triggers, prevention, treatment) | Genetic/Environmental Etiology | Long-term health/prognosis |
New Treatments | JM complications ( i.e. rash, calcinosis, lipodystrophy) | Fatigue |
Pain management | Risk of other autoimmune diseases | Flares (triggers, prevention, treatment) |